PD-1/PD-L1 blockade in renal cell cancer

Kathryn E. Beckermann*, Douglas B. Johnson, Jeffrey A. Sosman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


Introduction: Immunotherapy using checkpoint inhibitors is providing significant benefit to patients with renal cell carcinoma (RCC), both in overall survival and tolerability of treatment. Given the recent approval of the first checkpoint inhibitor in RCC, this review discusses the background and clinical data for checkpoint inhibition in RCC. Areas covered: This review introduces and discusses the basic biologic mechanisms of checkpoint inhibitor function and focuses on the current evidence in clinical trials for the use of immunotherapy in RCC. Expert commentary: Immunotherapy has been a mainstay of therapy in RCC, but the recent approval of nivolumab with ORR of 25% and durable responses has provided a transformative new therapeutic option.

Original languageEnglish (US)
Pages (from-to)77-84
Number of pages8
JournalExpert Review of Clinical Immunology
Issue number1
StatePublished - Jan 2 2017


  • PD-1
  • PD-L1
  • Renal cell
  • atezolizumab
  • nivolumab
  • pembrolizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'PD-1/PD-L1 blockade in renal cell cancer'. Together they form a unique fingerprint.

Cite this